US45579U1097
US45579U1097
Indivior Pharmaceuticals, Inc.
Loading chart...
Pure Price Volatility Risk (Market Swings)
The business itself is financially solid (Financial Health 75/100, minimal insolvency risk). The high overall score (7/7) is driven primarily by extreme stock price swings (±264.2% p.a.) and steep historical drawdowns.
Volatility Risk
Transparent evaluation of price volatility (SRI), Beta, and historical drawdowns.
Volatility Risk Score
7/7 Very High
7 / 7 SRI Price Fluctuation & Beta
Very high volatility or fundamental risks. Significant loss potential; strictly for aggressive investors. Largely moves in line with the broader market.
Beta (Market Relation)
1.18x
Above averageVolatility (5Y p.a.)
264.2% p.a.
5-Year HorizonMax Drawdown (5Y)
-85.5%
5-Year HorizonSharpe Ratio
0.06
Return / RiskSpeculative / High Risk: Score Basis:
Multi-Horizon Risk & Performance Matrix
Historical volatility, drawdowns, and risk-adjusted return across 1, 3, 5, and 10 years.
High Volatility
Timeframe | Volatility (p.a.) | Max Drawdown | Sharpe Ratio | Return (p.a.) |
|---|---|---|---|---|
| 1 Year | — | — | — | +47.3% |
| 3 Years | 55.0% | -67.6% | 0.32 | +20.2% |
| 5 Years | 264.2% | -85.5% | 0.06 | +18.9% |
| 10 Years | 197.0% | -93.8% | 0.02 | +6.3% |
Automated Risk & Health Notes (Red Flags)
Single Stock Risk: Investing in an individual stock carries full company and insolvency risk (no fund diversification).
Exemplary balance sheet strength: Very solid ratio of equity to debt.
🔴 Low analyst coverage – higher uncertainty in growth estimates & projections
Structurally High Volatility: Above-average fluctuations persist across 5 to 10 years (264.2% p.a.).
Historical Stress Test: Maximum peak-to-trough drawdown of -93.8% in the extended horizon.
Corporate Governance & ISS Scores
Overall Governance Risk
3 ISS Score: 3 / 10
Audit Risk
10 ISS Score: 10 / 10
Board Risk
1 ISS Score: 1 / 10
Short Ratio
5.60